Антибактериальная терапия при обострении хронической обструктивной болезни легких

хроническая обструктивная болезнь легких, обострение, антибактериальная терапия, биомаркеры

1. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI / WHO workshop report. Last updated 2008. www.goldcopd.org.

2. Burge S., Wedzicha J.A. COPD exacerbations: definitions and classifications. Eur. Respir. J. 2003; 21 (suppl. 41): 46s-53s.

3. Rodriguez-Roisin R. Toward a consensus definition for COPD exacerbations. Chest 2000; 117 (5, suppl. 2): 398S-401S.

4. Stanford R.H., Shen Y., McLaughlin T. Cost of chronic obstructive pulmonary disease in the emergency department and hospital: an analysis of administrative data from 218 US hospitals. Treat. Respir. Med. 2006; 5: 343-349.

5. O'Donnell D.E., Parker C.M. COPD exacerbations: Pathophysiology. Thorax 2006; 61: 354-361.

6. Donaldson G.C., Seemungal T.A.R., Bhowmik A., Wedzicha J.A. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax 2002; 57: 847-852.

7. Seemungal T.A.R., Donaldson G.C., Paul E.A. et al. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 1998; 151: 1418-1422.

8. Miravitlles M., Murio C., Guerrero T. et al. Pharmacoeconomic evaluation of acute exacerbations of chronic bronchitis and COPD. Chest 2002; 121: 1449-1455.

9. Celli B.R., Barnes P.J. Exacerbation of chronic obstructive pulmonary disease. Eur. Respir. J. 2007; 29: 1224-1238.

10. Seneff M.G., Wagner D.P., Wagner R.P. et al. Hospital and 1-year survival of patients admitted to intensive care units with acute exacerbation of chronic obstructive pulmonary disease. J. A. M. A. 1995; 274: 1852-1857.

11. Zielinski J., MacNee W., Wedzicha J. et al. Causes of death in patients with COPD and chronic respiratory failure. Monaldi Arch. Chest Dis. 1997; 52: 43-47.

12. Veeramachaneni S.B., Sethi S. Pathogenesis of bacterial exacerbations of COPD. COPD 2006; 3: 109-115.

13. White A.J., Gompertz S., Stockley R.A. Chronic obstructive pulmonary disease. 6: The aetiology of exacerbations of chronic obstructive pulmonary disease. Thorax 2003; 58: 73-80.

14. Monso E., Ruiz J., Rosell A. et al. Bacterial infection in chronic obstructive pulmonary disease: A study of stable and exacerbated outpatients using the protected specimen brush. Am. J. Respir. Crit. Care Med. 1995; 152: 1316-1320.

15. Pela R., Marchesani F., Agostinelli C. et al. Airways microbial flora in COPD patients in stable clinical conditions and during exacerbations: A bronchoscopic investigation. Monaldi Arch. Chest Dis. 1998; 53: 262-267.

16. Sethi S., Evans N., Grant B.J.B., Murphy T.F. New strains of bacteria and exacerbations of chronic obstructive pulmonary disease. N. Engl. J. Med. 2002; 347: 465-471.

17. Soler N., Torres A., Ewig S. et al. Bronchial microbial patterns in severe exacerbations of chronic obstructive pulmonary disease (COPD) requiring mechanical ventilation. Am. J. Respir. Crit. Care Med. 1998; 157: 1498-1505.

18. Fagon J.Y., Chastre J., Trouillet J.L. et al. Characterization of distal bronchial microflora during acute exacerbation of chronic bronchitis. Use of the protected specimen brush technique in 54 mechanically ventilated patients. Am. Rev. Respir. Dis. 1990; 142: 1004-1008.

19. Miravitlles M., Espinosa C., FernandezLaso E. et al. Relationship between bacterial flora in sputum and functional impairment in patients with acute exacerbations of COPD. Study Group of Bacterial Infection in COPD. Chest 1999; 116: 40-46.

20. Eller J., Ede A., Schaberg T. et al. Infective exacerbations of chronic bronchitis: relation between bacteriologic etiology and lung function. Chest 1998; 113: 1542-1548.

21. von Hertzen L., Isoaho R., Leinonen M. et al. Chlamydia pneumoniae antibodies in chronic obstructive pulmonary disease. Int. J. Epidemiol. 1996; 25: 658-664.

22. Mogulkoc N., Karakurt S., Isalska B. et al. Acute purulent exacerbation of chronic obstructive pulmonary disease and Chlamydia pneumoniae infection. Am. J. Respir. Crit. Care Med. 1999; 160: 349-353.

23. Diederen B.M., van der Valk P.D., Kluytmans J.A. et al. The role of atypical respiratory pathogens in exacerbations of chronic obstructive pulmonary disease. Eur. Respir. J. 2007; 30: 240-244.

24. Ball P., Harris J.M., Lowson D. et al. Acute infective exacerbations of chronic bronchitis. Q. J. Med. 1995; 88: 61-68.

25. Papi A. et al. Infections and airway inflammation in chronic obstructive pulmonary disease severe exacerbations. Am. J. Respir. Crit. Care Med. 2006; 173 (10): 1114-1121.

26. Seemungal T., Donaldson G.C., Breuer J. et al. Rhinoviruses are associated with exacerbations of COPD. Eur. Respir. J. 1998; 12 (suppl. 28): 298s.

27. Sethi S., Murphy T.F. Infection in the pathogenesis and course of chronic obstructive pulmonary disease. N. Engl. J. Med. 2008; 359: 2355-2365.

28. Hirschmann J.V. Do bacteria cause exacerbations of COPD? Chest 2000; 118: 193-203.

29. Sachs A.P.E., Koeter G.H., Groenier K.H. et al. Changes in symptoms, peak expiratory flow, and sputum flora during treatment with antibiotics of exacerbations in patients with chronic obstructive pulmonary disease in general practice. Thorax 1995; 50: 758-763.

30. Puhan M.A., Vollenweider D., Latshang T. et al. Exacerbations of chronic obstructive pulmonary disease: when are antibiotics indicated? A systematic review. Respir. Res. 2007; 8: 30.

31. Anthonisen N.R., Manfreda J., Warren C.P.W. et al. Antibiotic therapy in acute exacerbations of chronic obstructive pulmonary disease. Ann. Intern. Med. 1987; 106: 196-204.

32. Nouira S., Marghli S., Belghith M. et al. Once daily oral ofloxacin in chronic obstructive pulmonary disease exacerbations requiring mechanical ventilation: a randomised placebo-controlled trial. Lancet 2001; 358: 2020-2025.

33. Wilson R., Allegra L., Huchon G. et al. Short-term and long-term outcomes of moxifloxacin compared to standard antibiotic treatment in acute exacerbations of chronic bronchitis. Chest 2004; 125: 953-964.

34. Chodosh S. Clinical significance of the infection-free interval in the management of acute bacterial exacerbations of chronic bronchitis. Chest 2005; 127: 2231-2236.

35. Adams S., Melo J., Luther M. et al. Antibiotics are associated with lower relapse rates in outpatients with acute exacerbations of chronic obstructive pulmonary disease. Chest 2000; 117: 1345-1352.

36. Roede B.M., Bresser P., Prins J.M. et al. Reduced risk of next exacerbation and mortality associated with antibiotic use in COPD. Eur. Respir. J. 2009; 33: 282-288.

37. Celli B.R., MacNee W. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS / ERS position paper. Eur. Respir. J. 2004; 23: 932-946.

38. Stockley R.A., O'Brien C., Pye A., Hill S.L. Relationship of sputum color to nature and outpatient management of acute exacerbations of COPD. Chest 2000; 117: 1638-1645.

39. Soler N., Agustí C., Angrill J. et al. Bronchoscopic validation of the significance of sputum purulence in severe exacerbations of chronic obstructive pulmonary disease. Thorax 2007; 62: 29-35.

40. Nseir S., Ader F. Prevalence and outcome of severe chronic obstructive pulmonary disease exacerbations caused by multidrug-resistant bacteria. Curr. Opin. Pulm. Med. 2008; 14: 95-100.

41. Lacoma A., Prat C., Andreo F., Dominguez J. Biomarkers in the management of COPD. Eur. Respir. Rev. 2009; 18 (112): 96-104.

42. Christ-Crain M., Müller B. Biomarkers in respiratory tract infections: diagnostic guides to antibiotic prescription, prognostic markers and mediators. Eur. Respir. J. 2007; 30: 556-573.

43. Nylen E.S., Snider R.H., Thompson K.A. et al. Pneumonitis-associated hyperprocalcitoninemia. Am. J. Med. Sci. 1996; 312: 12-18.

44. Boussekey N., Leroy O., Alfandari S. et al. Procalcitonin kinetics in the prognosis of severe community-acquired pneumonia. Intensive Care Med. 2006; 32: 469-472.

45. Becker K.L., Nylen E.S., White J.C. et al. Procalcitonin and the calcitonin gene family of peptides in inflammation, infection, and sepsis: a journey from calcitonin back to its precursors. J. Clin. Endocrinol. Metab. 2004; 89: 1512-1525.

46. Stolz D., Christ-Crain M., Bingisser R. et al. Antibiotic treatment of exacerbations of COPD. A randomized, controlled trial comparing procalcitonin-guidance with standard therapy. Chest 2007; 131: 9-19.

47. Pepys M.B., Berger A. The renaissance of C-reactive protein. Brit. Med. J. 2001; 322: 4-5.

48. Kolb-Bachofen V. A review on the biological properties of C-reactive protein. Immunobiology 1991; 183: 133-145.

49. Ballou S.P., Kushner I. C-reactive protein and the acute phase response. Adv. Intern. Med. 1992; 37: 313-336.

50. Gewurz H., Zhang X., Lint T. Structure and function of the pentraxins. Curr. Opin. Immunol. 1995; 7: 54-64.

51. Shine B., de Beer F.C., Pepys M.B. Solid phase radioimmunoassays for human Creactive protein. Clin. Chim. Acta 1981; 117: 13-23.

52. Hutchinson W.L. et al. Immunoradiometric assay of circulating C-reactive protein: agerelated values in the adult general population. Clin. Chem. 2000; 46: 934-938.

53. Hurst J.R., Donaldson G.C., Perera W.R. Use of plasma biomarkers at exacerbation of chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2006; 174: 867-874.

54. Dev D., Sankaran E.W.R., Cunnife J. et al. Value of C-reactive protein in exacerbation of chronic obstructive pulmonary disease. Respir. Med. 1998; 92: 664-667.

55. Baimakanova G., Zubairova P., Avdeev S., Chuchalin A. Performance of rapid, bedside whole blood C-reactive protein (СRP) test as a diagnostic test for bacterial infection and pneumonia in patients with acute exacerbation of chronic obstructive pulmonary disease. Eur. Respir. J. 2007; 29 (suppl.): 556s.

56. Авдеев С.Н., Баймаканова Г.Е., Зубаирова П.А. Возможности С-реактивного белка в диагностике бактериальной инфекции и пневмонии у больных с обострением хронической обструктивной болезни легких. Уральский мед. журнал 2008; 13: 19-24.

57. Martinez F.J., Han M.K., Flaherty K., Curtis J. Role of infection and antimicrobial therapy in acute exacerbations of chronic obstructive pulmonary disease. Expert. Rev. Antiinfect. Ther. 2006; 4: 101-124.

58. Ram F.S., Rodriguez-Roisin R., Granados-Navarrete A. et al. Antibiotics for exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. (database online). Issue 2; 2006.

59. Grossman R.F. Guidelines for the treatment of acute exacerbations of chronic bronchitis. Chest 1997; 112 (suppl.): 310S-313S.

60. Wilson R., Jones P., Schaberg T. et al. Antibiotic treatment and factors influencing short and long term outcomes of acute exacerbations of chronic bronchitis. Thorax 2006; 61: 337-342.

61. Dimopoulos G., Siempos I.I., Korbila I.P. et al. Comparison of firstline with second-line antibiotics for acute exacerbations of chronic bronchitis: a meta-analysis of randomized controlled trials. Chest 2007; 132: 447-455.

62. Siempos I.I., Dimopoulos G., Korbila I.P. et al. Macrolides, quinolones and amoxicillin / clavulanate for chronic bronchitis: a meta-analysis. Eur. Respir. J. 2007; 29: 1127-1137.

63. Contopoulos-Loannidis D.G., Ioannidis J.P.A., Chewc P., Law J. Meta-analysis of randomized controlled trials on the comparative efficacy and safety of azithromycin against other antibiotics for lower respiratory tract infections. J. Antimicrob. Chemother. 2001; 48: 691-703.

64. Dukes M.N.G., ed. Meyler's side effects of drugs. 13th ed. USA: Elsevier Science; 1996.

65. Козлов Р.С., Сивая О.В., Шпынев К.В. и др. Антибиотикорезистентность Streptococcus pneumoniae в России в 1999-2005 гг.: результаты многоцентровых проспективных исследований ПеГАС-I и ПеГАС-II. Клин. микробиол. и антимикроб. химиотер. 2006; 8: 33-47.

66. Hoepelman I.M., Mollers M.J., van Schie M.H. et al. A short (3-day) course of azithromycin tablets versus a 10-day course of amoxycillin-clavulanic acid (co-amoxiclav) in the treatment of adults with lower respiratory tract infections and effects on long-term outcome. Int. J. Antimicrob. Agents 1998; 9: 141-146.

67. Anzueto A., Fisher C.L.Jr., Busman T., Olson C.A. Comparison of the efficacy of extended-release clarithromycin tablets and amoxicillin / clavulanate tablets in the treatment of acute exacerbation of chronic bronchitis. Clin. Ther. 2001; 23: 72-86.

68. Castaldo R.S., Celli B.R., Gomez F. et al. A comparison of 5-day courses of dirithromycin and azithromycin in the treatment of acute exacerbations of chronic obstructive pulmonary disease. Clin. Ther. 2003; 25: 542-557.

69. Amsden G.W., Baird I.M., Simon S., Treadway G. Efficacy and safety of azithromycin versus levofloxacin in the outpatient treatment of acute bacterial exacerbations of chronic bronchitis. Chest 2003; 123: 772-777.

70. Andre-Alves M.R., Jardim J.R., Silva R.F. et al. Comparison between azithromycin and amoxicillin in the treatment of infectious exacerbation of chronic obstructive pulmonary disease. J. Bras. Pneumol. 2007; 33: 43-50.

71. Rubin B.K. Immunomodulatory properties of macrolides: overview and historical perspective. Am. J. Med. 2004; 117 (9A): 2S-4S.

72. EUCAST Expert rules in antimicrobial susceptibility test ing, version 1, April 2008. www.eucast.org

73. O'Donnell J.A., Gelone S.P. The newer fluoroquinolones. Infect. Dis. Clin. N. Am. 2004; 18: 691-716.

74. Blasi F., Tarsia P., Aliberti S. et al. Highlights on the appropriate use of fluoroquinolones in respiratory tract infections. Pulm. Pharmacol. Ther. 2006; 19: 11-19.

75. Bonfiglio G. Is levofloxacin as active as ciprofloxacin against Pseudomonas aeruginosa? Chemotherapy 2001; 47: 239-242.

76. Антибиотикорезистентность в России: Возбудители внебольничных инфекций. www.antibiotic.ru

77. Société de Pathologie Infectieuse de Langue Française. 15th consensus conference about management of lower respiratory tract infections in immunocompetent adult. Med. Mal. Infect. 2006; 36: 235-244.

78. Сидоренко С.В., Козлов С.Н. Группа пенициллинов. В кн.: Практическое руководство по антиинфекционной химиотерапии / под ред. Страчунского Л.С., Белоусова Ю.Б., Козлова С.Н. М.; 2002. 47-55.

79. Дворецкий Л.И., Дубровская Н.В., Грудинина С.А. и др. Клинико-микробиологический мониторинг больных с обострением хронического бронхита, леченных антибактериальными препаратами. Тер. архив 2006; 78 (3): 25-35.

80. Neu H.C., Wilson A.P.R., Gruneberg R.N. Amoxycillin / clavulanic acid: a review of its efficacy in over 38,500 patients from 1979 to 1992. J. Chemother. 1993; 5: 67-93.

81. Карпов О.И. Флемоклав Солютаб - новая лекарственная форма амоксициллина / клавуланата в лечении синусита. Клин. фармакол. и терапия 2006; 15 (4): 1-4.

82. Cortvriendt W.R., Verschoor J.S., Hespe W. Bioavailability study of a new amoxicillin tablet designed for several modes of oral administration. Arzneimittelforschung 1987; 37: 977-979.

83. Sourgens H., Steinbrede H., Verschoor J.S. et al. Bioequivalence study of a novel Solutab tablet formulation of amoxicillin / clavulanic acid versus the originator film-coated tablet. Int. J. Clin. Pharmacol. Ther. 2001; 39: 75-82.

84. Гучев И.А., Козлов Р.С. Безопасность и эффективность различных лекарственных форм амоксициллина / клавулановой кислоты при инфекциях нижних дыхательных путей у взрослых: открытое проспективное рандомизированное исследование. Пульмонология 2008; 2: 73-80.

85. Sethi S., Breton J., Wynne B. Efficacy and safety of pharmacokinetically enhanced amoxicillin-clavulanate at 2,000/ 125 milligrams twice daily for 5 days versus amoxicillin clavulanate at 875 / 125 milligrams twice daily for 7 days in the treatment of acute exacerbations of chronic bronchitis. Antimicrob. Agents Chemother. 2005; 49: 153-160.

86. Álvarez-Sala J.L., Kardos P., Martínez-Beltrán J. et al. Clinical and bacteriological efficacy in treatment of acute exacerbations of chronic bronchitis with cefditoren-pivoxil versus cefuroxime-axetil. Antimicrob. Agents Chemother. 2006; 50: 1762-1767.

87. Chodosh S., DeAbate C.A., Haverstock D. et al. Short-course moxifloxacin therapy for treatment of acute bacterial exacerbations of chronic bronchitis. The Bronchitis Study Group. Respir. Med. 2000; 94: 18-27.

88. Wilson R., Schentag J.J., Ball P., Mandell L. for the 068 Study Group. A comparison of gemifloxacin and clarithromycin in acute exacerbations of chronic bronchitis and long-term clinical outcomes. Clin. Ther. 2002; 4: 639-652.

89. Sethi S., Fogarty C., Fulambarker A. A randomized, double-blind study comparing 5 days oral gemifloxacin with 7 days oral levofloxacin in patients with acute exacerbation of chronic bronchitis. Respir. Med. 2004; 98: 697-707.

90. Fogarty C., De Wet R., Mandell L. et al. Five-day telithromycin once daily is as effective as 10-day clarithromycin twice daily for the treatment of acute exacerbations of chronic bronchitis and is associated with reduced health- care resource utilization. Chest 2005; 128: 1980-1988.

91. Guay D.R.P. Short-course antimicrobial therapy of respiratory tract infections. Drugs 2003; 63: 2169-2184.

92. Kardas R. Patient compliance with antibiotic treatment for respiratory tract infections. J. Antimicrob. Chemother. 2002; 49: 897-903.

93. El Moussaoui R., Roede B.M., Speelman P. et al. Short-course antibiotic treatment in acute exacerbations of chronic bronchitis and COPD: a meta-analysis of double-blind studies. Thorax 2008; 63: 415-422.

94. Roede B.M., Bresser P., El Moussaoui R. et al. Three vs 10 days of amoxycillin-clavulanic acid for type 1 acute exacerbations of chronic obstructive pulmonary disease: a randomised, double-blind study. Clin. Microbiol. Infect. 2007; 13: 284-290.

95. Christ-Crain M., Stolz D., Bingisser R. et al. Procalcitonin guidance of antibiotic therapy in community-acquired pneumonia: a randomized trial. Am. J. Respir. Crit. Care Med. 2006; 174: 84-93.

96. Nobre V., Harbarth S., Graf J.D. et al. Use of procalcitonin to shorten antibiotic treatment duration in septic patients: A randomized trial. Am. J. Respir. Crit. Care Med. 2008; 177: 498-505.